PEAQXCAS# 459836-30-7 |
- GSK2334470
Catalog No.:BCC4982
CAS No.:1227911-45-6
- BX-912
Catalog No.:BCC1250
CAS No.:702674-56-4
- OSU-03012 (AR-12)
Catalog No.:BCC1255
CAS No.:742112-33-0
- NVP-BAG956
Catalog No.:BCC1813
CAS No.:853910-02-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 459836-30-7 | SDF | Download SDF |
PubChem ID | 9868551 | Appearance | Powder |
Formula | C17H17BrN3O5P | M.Wt | 454.21 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | NVP-AAM077 | ||
Solubility | Soluble in DMSO | ||
Chemical Name | [[[(1S)-1-(4-bromophenyl)ethyl]amino]-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid | ||
SMILES | CC(C1=CC=C(C=C1)Br)NC(C2=C3C(=CC=C2)NC(=O)C(=O)N3)P(=O)(O)O | ||
Standard InChIKey | XXZGNAZRWCBSBK-WFVOFKTRSA-N | ||
Standard InChI | InChI=1S/C17H17BrN3O5P/c1-9(10-5-7-11(18)8-6-10)19-17(27(24,25)26)12-3-2-4-13-14(12)21-16(23)15(22)20-13/h2-9,17,19H,1H3,(H,20,22)(H,21,23)(H2,24,25,26)/t9-,17?/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
PEAQX Dilution Calculator
PEAQX Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2016 mL | 11.0081 mL | 22.0162 mL | 44.0325 mL | 55.0406 mL |
5 mM | 0.4403 mL | 2.2016 mL | 4.4032 mL | 8.8065 mL | 11.0081 mL |
10 mM | 0.2202 mL | 1.1008 mL | 2.2016 mL | 4.4032 mL | 5.5041 mL |
50 mM | 0.044 mL | 0.2202 mL | 0.4403 mL | 0.8806 mL | 1.1008 mL |
100 mM | 0.022 mL | 0.1101 mL | 0.2202 mL | 0.4403 mL | 0.5504 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC50=270 nM), rather than 1A/2B(29,600 nM). IC50 value: 270 nM(hNMDA A1/A2) [1] Target: NR2A antagonist in vitro: PEAQX has a high binding affinity for NMDA receptors (IC50=8 nM), and a functional preference in excess of 100-fold for hNMDA 1A/2A (IC50=of 270 nM) over 1A/2B receptors (IC50=29,600 nM) [1]. in vivo: PEAQX is practically inactive in Xenopus oocytes expressing hNMDA 1A/2B receptors, displays an ED50 value of 23 mg/kg in the MES test [1]. Sprague-Dawley rats were treated on PN7, PN9, and PN11 with PCP (10 mg/kg), PEAQX (NR2A-preferring antagonist; 10, 20, or 40 mg/kg), or ifenprodil (selective NR2B antagonist; 1, 5, or 10 mg/kg) and sacrificed for measurement of caspase-3 activity (an index of apoptosis) or allowed to age and tested for locomotor sensitization to PCP challenge on PN28-PN35. PCP or PEAQX on PN7, PN9, and PN11 markedly elevated caspase-3 activity in the cortex; ifenprodil showed no effect. Striatal apoptosis was evident only after subchronic treatment with a high dose of PEAQX (20 mg/kg). Animals treated with PCP or PEAQX on PN7, PN9, and PN11 showed a sensitized locomotor response to PCP challenge on PN28-PN35 [2].
References:
[1]. Auberson YP, et al. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1099-102.
[2]. Anastasio NC, et al. Differential role of N-methyl-D-aspartate receptor subunits 2A and 2B in mediating phencyclidine-induced perinatal neuronal apoptosis and behavioral deficits. Neuroscience. 2009 Nov 10;163(4):1181-91.
- Obeticholic Acid
Catalog No.:BCC5572
CAS No.:459789-99-2
- SB 452533
Catalog No.:BCC7620
CAS No.:459429-39-1
- JNJ-7777120
Catalog No.:BCC4543
CAS No.:459168-41-3
- SW033291
Catalog No.:BCC3981
CAS No.:459147-39-8
- Boc-Asn-ONp
Catalog No.:BCC3072
CAS No.:4587-33-1
- Ilicic acid
Catalog No.:BCN5505
CAS No.:4586-68-9
- Curcumin
Catalog No.:BCN5504
CAS No.:458-37-7
-
Scutebarbatine L
Catalog No.:BCN8369
CAS No.:960302-91-4
- BMS 470539 dihydrochloride
Catalog No.:BCC7850
CAS No.:457893-92-4
- PA 452
Catalog No.:BCC8005
CAS No.:457657-34-0
- Pyridone 6
Catalog No.:BCC1874
CAS No.:457081-03-7
- 1alpha, 24, 25-Trihydroxy VD2
Catalog No.:BCC1298
CAS No.:457048-34-9
- 5-[(2R)-2-Aminopropyl]-2,3-dihydro-1-[3-(phenylmethoxy)propyl]-1H-indole-7-carbonitrile
Catalog No.:BCN1438
CAS No.:459868-73-6
- Rucaparib (AG-014699,PF-01367338)
Catalog No.:BCC2207
CAS No.:459868-92-9
- Interiotherin C
Catalog No.:BCN3636
CAS No.:460090-65-7
- Larixyl acetate
Catalog No.:BCC8195
CAS No.:4608-49-5
- Eact
Catalog No.:BCC6313
CAS No.:461000-66-8
- Ko 143
Catalog No.:BCC1684
CAS No.:461054-93-3
- Dapagliflozin
Catalog No.:BCC2552
CAS No.:461432-26-8
- 4beta,12-dihydroxyguaian-6,10-diene
Catalog No.:BCN7829
CAS No.:461644-90-6
- Lactulose
Catalog No.:BCC4669
CAS No.:4618-18-2
- Gnemonol B
Catalog No.:BCN3399
CAS No.:462636-74-4
- alpha-Linolenic acid
Catalog No.:BCN8319
CAS No.:463-40-1
- Bay 55-9837
Catalog No.:BCC5932
CAS No.:463930-25-8
The effects of an acute challenge with the NMDA receptor antagonists, MK-801, PEAQX, and ifenprodil, on social inhibition in adolescent and adult male rats.[Pubmed:24043344]
Psychopharmacology (Berl). 2014 Apr;231(8):1797-807.
RATIONALE: NMDA antagonists consistently produce social inhibition in adult animals, although effects of these manipulations on social behavior of adolescents are relatively unknown. OBJECTIVES: The aim of this study was to assess potential age differences in the socially inhibitory effects of the non-competitive NMDA antagonist, MK-801, as well as NR2 subunit selective effects, given the regional and developmental differences that exist for the NR2 subunit during ontogeny. METHODS: In separate experiments, adolescent and adult male Sprague-Dawley rats were treated acutely with MK-801 (0, 0.05, 0.1, 0.2 mg/kg, i.p.), the NR2A antagonist, PEAQX (2.5, 5, 10, 20 mg/kg, s.c.), or the NR2B antagonist, ifenprodil (1.5, 3, 6, 12 mg/kg, i.p.), 10 min prior to a social interaction test. RESULTS: Adolescents required higher doses of MK-801 (0.1 and 0.2 mg/kg) to induce social suppression, whereas adults demonstrated reductions in social activity after all doses. Likewise, adolescents required higher doses of ifenprodil (6 and 12 mg/kg) to produce social inhibitory effects relative to adults (all doses). In contrast, adults were less sensitive to PEAQX than adolescents, with adults showing social inhibition after 20 mg/kg whereas adolescents showed this effect following 10 and 20 mg/kg. Although locomotor activity was generally reduced at both ages by all drugs tested, ANCOVAs using locomotor activity as a covariate revealed similar patterns of social inhibitory effects. CONCLUSIONS: Adolescents are less sensitive than adults to the disruption of social behavior by NMDA and NR2B-selective receptor antagonism, but not by an NR2A antagonist-age differences that may be related to different subunit expression patterns during development.
Low doses of the NMDA receptor antagonists, MK-801, PEAQX, and ifenprodil, induces social facilitation in adolescent male rats.[Pubmed:23651880]
Behav Brain Res. 2013 Aug 1;250:18-22.
Adolescents display high levels of interactions with peers relative to other age groups, with these interactions further enhanced by ethanol under some circumstances. Understanding of the neural mechanisms underlying these high levels of social interactions is important given that alcohol use is initiated during adolescence and adolescents tend to report drinking for social reasons. Given that ethanol's effects are associated in part with functional antagonism of the NMDA receptor system, the current experiment explored the role of NMDA antagonists for facilitating adolescent social behavior. Adolescent male Sprague-Dawley rats were challenged acutely with either the non-competitive NMDA antagonist, MK-801 (0.01, 0.03mg/kg), the NR2A antagonist, PEAQX (1.25, 3.75mg/kg) or the NR2B antagonist, ifenprodil (0.75, 2.25mg/kg) 30min prior to a 10-min social interaction test. All compounds generally increased overall social activity (i.e., sum of social investigation, contact behavior, and play), with ifenprodil also significantly enhancing play and social contact behaviors. Although the frequencies of peer-directed social behaviors were typically greater following administration with these NMDA antagonists, social preference, indexed via the number of crossovers to the side with the partner relative to crossovers away, was significantly reduced in MK-801 and PEAQX-treated rats. None of these changes were associated with concomitant alterations in overall locomotor activity under these test circumstances. These data support the suggestion that the increases in social interactions observed in adolescents following acute ethanol may be driven in part by NMDA receptor antagonism - particularly of the NR2B subunit - given that ifenprodil stimulated social behavior in a manner similar to that produced by low doses of ethanol.